Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$67.24 USD

67.24
1,468,848

+0.13 (0.19%)

Updated Apr 23, 2024 12:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights Merck, ServiceNow, Blackstone, Gilead Sciences and Diageo

Merck, ServiceNow, Blackstone, Gilead Sciences and Diageo are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Merck, ServiceNow & Blackstone

Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), ServiceNow, Inc. (NOW) and Blackstone Inc. (BX).

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?

Smart Beta ETF report for VALQ

Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates

Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.

Yashwardhan Jain headshot

Where Are Biotech ETFs Headed After Q4 Earnings?

Look into how Biotech ETFs performed after Q4 earnings.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline

Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.

Company News for Feb 13, 2024

Companies In The Article Are: FANG, JOBY,C, CBAY and GILD

Should You Invest in the VanEck Biotech ETF (BBH)?

Sector ETF report for BBH

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO

Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO are included in this Analyst Blog.

Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More

Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.

Company News for Feb 8, 2024

Companies in The News Are: ARCC,EMR,F,GILD

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Gilead (GILD) Q4 Earnings Miss Estimates, Sales Top on Veklury

Gilead (GILD) posts mixed results for the fourth quarter. Sales beat estimates on the better-than-expected performance of Veklury due to higher hospitalizations at the end of 2023.

Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Mark Vickery headshot

Late-Session Earnings Bonanza: Ford, Chipotle, Snap & More

Markets bounced back this Tuesday from a Monday sell-off, though not all the way back to Friday highs.

Earnings Data Deluge

Earnings Data Deluge.

Mark Vickery headshot

Earnings, Fed Speakers Dominate Activity; Lilly Beats, Spotify Misses

Investors of Lilly (LLY) are responding to the eye-opening efficacy of obesity drugs Mounjaro and Zepbound.

Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More

Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.

Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2023 results.

Exploring Analyst Estimates for Gilead (GILD) Q4 Earnings, Beyond Revenue and EPS

Evaluate the expected performance of Gilead (GILD) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why

Gilead Sciences (GILD) reachead $79.07 at the closing of the latest trading day, reflecting a -0.57% change compared to its last close.